211 related articles for article (PubMed ID: 19278961)
1. Novel agents on the horizon for cancer therapy.
Ma WW; Adjei AA
CA Cancer J Clin; 2009; 59(2):111-37. PubMed ID: 19278961
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in breast cancer: where are we now?
Di Cosimo S; Baselga J
Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
[TBL] [Abstract][Full Text] [Related]
3. Future novel single agent and combination therapies.
Cirstea D; Vallet S; Raje N
Cancer J; 2009; 15(6):511-8. PubMed ID: 20010171
[TBL] [Abstract][Full Text] [Related]
4. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
5. Novel combinations based on epidermal growth factor receptor inhibition.
Adjei AA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4446s-4450s. PubMed ID: 16857826
[TBL] [Abstract][Full Text] [Related]
6. Novel agents in development for pediatric sarcomas.
Hughes DP
Curr Opin Oncol; 2009 Jul; 21(4):332-7. PubMed ID: 19444103
[TBL] [Abstract][Full Text] [Related]
7. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
8. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
Bertoni E; Salvadori M
J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
[TBL] [Abstract][Full Text] [Related]
9. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
Broxterman HJ; Georgopapadakou NH
Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.
Tao Y; Pinzi V; Bourhis J; Deutsch E
Nat Clin Pract Oncol; 2007 Oct; 4(10):591-602. PubMed ID: 17898809
[TBL] [Abstract][Full Text] [Related]
12. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
13. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
Johnston SR
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
[TBL] [Abstract][Full Text] [Related]
14. Key cancer cell signal transduction pathways as therapeutic targets.
Bianco R; Melisi D; Ciardiello F; Tortora G
Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
[TBL] [Abstract][Full Text] [Related]
15. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
Hendrickson AW; Haluska P
Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic protein kinase inhibitors.
Grant SK
Cell Mol Life Sci; 2009 Apr; 66(7):1163-77. PubMed ID: 19011754
[TBL] [Abstract][Full Text] [Related]
18. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
19. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.
Ota H; Tokunaga E; Chang K; Hikasa M; Iijima K; Eto M; Kozaki K; Akishita M; Ouchi Y; Kaneki M
Oncogene; 2006 Jan; 25(2):176-85. PubMed ID: 16170353
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of growth factor signalling.
Wakeling AE
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S183-7. PubMed ID: 16113095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]